Anti-PT seroprevalence at T1 in all villages according to age category.

a<p>Chi-square test has been performed.</p>b<p>Kruskal-Wallis test between IgG responses according to the villages.</p>c<p>Mann-Whitney test has been performed for children of the same villages.</p

PT-IgG >30 IU/ml at T1 according to age categories and villages.

<p>Percentages of children with PT-IgG >30 IU/ml at the first visit in every village.</p><p>Total number of children within age category is in brackets.</p

Description of the cohort at the beginning of the survey (T1).

a<p>ANOVA test of age differences between children of all villages, and between ages of children of all villages according to their vaccination status.</p>b<p>Chi-square test to assess the gender distribution among villages and distribution of children within villages according to their vaccination status.</p><p>2 children were not vaccinated, one from Fanaye, and the other from Pendao.</p

Flow of participants through the study.

<p>Flow of participants through the study.</p

Seroprevalence of anti-PT IgG concentrations according to the village and visit for children younger (panel A) and older than 3 years (panel B).

<p>Chi-square test between seropositive children (anti-PT IgG concentration >30 IU/ml) and seronegative children at each visit within villages: panel A.: Agniam, <b>p = 0.3588</b>; Fanaye, p = 0.5227; Niandane, p = 0.4056; Pendao, p = 0.4276; Guédé, p = 0.9928; panel B.: Agniam, <b>p<0.0008</b>; Fanaye, p = 0.7641; Niandane, p = 0.2280; Pendao, p = 0.3292; Guédé, p = 0.1754.</p

PT-IgG responses at T1.

a<p>One-way ANOVA between IgG responses according to villages.</p>b<p>Chi-square test between seroprevalence according to villages.</p

Seroconversion throughout the visits in each village.

<p>Chi-square test between number of seroconverters (sera becoming newly positive to PT) and rest of population from the village.</p

Evaluation of antibody response to in children according to exposure of or vectors-3

<p><b>Copyright information:</b></p><p>Taken from "Evaluation of antibody response to in children according to exposure of or vectors"</p><p>http://www.malariajournal.com/content/6/1/117</p><p>Malaria Journal 2007;6():117-117.</p><p>Published online 1 Sep 2007</p><p>PMCID:PMC2008208.</p><p></p>t (BHN) and IgG levels (ΔDO)

Evaluation of antibody response to in children according to exposure of or vectors-1

<p><b>Copyright information:</b></p><p>Taken from "Evaluation of antibody response to in children according to exposure of or vectors"</p><p>http://www.malariajournal.com/content/6/1/117</p><p>Malaria Journal 2007;6():117-117.</p><p>Published online 1 Sep 2007</p><p>PMCID:PMC2008208.</p><p></p>d 75percentiles, and whiskers for 10and 90percentiles. The upper whisker extends to the largest value below the 75th percentile plus the box height multiplied by 1.5. n = number of children with or without malaria positive infection

Evaluation of antibody response to in children according to exposure of or vectors-4

<p><b>Copyright information:</b></p><p>Taken from "Evaluation of antibody response to in children according to exposure of or vectors"</p><p>http://www.malariajournal.com/content/6/1/117</p><p>Malaria Journal 2007;6():117-117.</p><p>Published online 1 Sep 2007</p><p>PMCID:PMC2008208.</p><p></p>hildren presents for all passages (n = 62/passage in Mboula and 89/passage in Gankette Balla). Figure 1C showed median values of antibody levels (expressed in median values) in children from Mboula and Gankette Balla. NS = No Significant